Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity

Anti-ErbB2 antibodies are well researched for the therapy of ErbB2-overexpressing tumors. The therapeutic potential and efficacy of these antibodies are closely related to their affinities to ErbB2. Previously we reported that an anti-ErbB2 antibody A21 targeting a conformational epitope comprising several loops in ErbB2 extracellular subdomain I and II could inhibit the proliferation of ErbB2-overexpressing cancer cells in vitro and in vivo. Here we found that another structureless and non-conserved loop in subdomain I of ErbB2 extracellular domain (ECD) was important for binding to A21, and then the antigen-contact sites on A21 were determined by site-directed mutation. The loop was constructed by molecular modeling, and a new model of A21-ErbB2 complex was generated by docking using the crystal structure of the scfv A21 and the model of ErbB2 ECD with the loop built. Based on the complex model, computational design for A21 affinity improvement was performed to enhance its affinity to ErbB2. Two mutants with about 1.7-fold improvement in affinity were obtained. Our study provided a rational molecular basis for affinity improvement and mechanism investigation of A21.

[1]  Navin Pokala,et al.  Energy functions for protein design I: Efficient and accurate continuum electrostatics and solvation , 2004, Protein science : a publication of the Protein Society.

[2]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[3]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  K. Tsumoto,et al.  Structural Consequences of Mutations in Interfacial Tyr Residues of a Protein Antigen-Antibody Complex , 2007, Journal of Biological Chemistry.

[5]  M. Lemmon,et al.  The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes* , 2002, The Journal of Biological Chemistry.

[6]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[7]  T. K. Yeung,et al.  Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. , 1999, Molecular biology of the cell.

[8]  Yinhua Yu,et al.  Antibody‐induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c‐erbb‐2 (her‐2/neu) gene product p185 , 1993, International journal of cancer.

[9]  J. Baselga,et al.  Mechanism of action of anti-HER2 monoclonal antibodies. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  I. Mian,et al.  Structure, function and properties of antibody binding sites. , 1991, Journal of molecular biology.

[11]  N. Hynes,et al.  A new therapeutic antibody masks ErbB2 to its partners. , 2004, Cancer cell.

[12]  T. Masuko,et al.  Molecular structural and functional characterization of tumor suppressive anti-ErbB-2 monoclonal antibody by phage display system. , 2003, Journal of biochemistry.

[13]  Bruce Tidor,et al.  Computational design of antibody-affinity improvement beyond in vivo maturation , 2007, Nature Biotechnology.

[14]  P. Evans,et al.  A structural explanation for the recognition of tyrosine-based endocytotic signals. , 1998, Science.

[15]  G. Cohen,et al.  Interactions of protein antigens with antibodies. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Martyn D Winn,et al.  Single-molecule imaging and fluorescence lifetime imaging microscopy show different structures for high- and low-affinity epidermal growth factor receptors in A431 cells. , 2008, Biophysical journal.

[17]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[18]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using Modeller , 2006, Current protocols in bioinformatics.

[19]  Y. Yarden,et al.  Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Y. Yarden,et al.  Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis , 2009, Proceedings of the National Academy of Sciences.

[21]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[22]  Siyi Hu,et al.  Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris. , 2006, Protein expression and purification.

[23]  Z. Weng,et al.  ZDOCK: An initial‐stage protein‐docking algorithm , 2003, Proteins.

[24]  T. N. Bhat,et al.  Small rearrangements in structures of Fv and Fab fragments of antibody D 1.3 on antigen binding , 1990, Nature.

[25]  R. Bast,et al.  Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c‐erbB‐2 (HER‐2/neu) gene product p185 , 1999, International journal of cancer.

[26]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[27]  C. Chothia,et al.  The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.

[28]  B. van Deurs,et al.  Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. , 2004, Molecular biology of the cell.

[29]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[30]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[31]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[32]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[33]  J. Novotný,et al.  Structural analysis of the ErbB‐2 receptor using monoclonal antibodies: Implications for receptor signalling , 2003, International journal of cancer.

[34]  Y. Yarden,et al.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. , 2000, Cancer research.

[35]  I. Wilson,et al.  Structural evidence for induced fit as a mechanism for antibody-antigen recognition. , 1994, Science.

[36]  Sachdev S Sidhu,et al.  Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. D'alessio,et al.  A new human antitumor immunoreagent specific for ErbB2. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[39]  U. Nielsen,et al.  Selection of tumor-specific internalizing human antibodies from phage libraries. , 2000, Journal of molecular biology.

[40]  E C Nice,et al.  Stoichiometry, Kinetic and Binding Analysis of the Interaction between Epidermal Growth Factor (EGF) and the Extracellular Domain of the EGF Receptor , 2000, Growth factors.

[41]  Siyi Hu,et al.  Epitope mapping and structural analysis of an anti‐ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism , 2008, Proteins.

[42]  Edouard C. Nice,et al.  Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis* , 2005, Journal of Biological Chemistry.

[43]  A. Bogan,et al.  Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.

[44]  L. E. Johannessen,et al.  The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. , 2005, Molecular biology of the cell.

[45]  R. Neve,et al.  Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. , 2001, Biochemical and biophysical research communications.

[46]  P. Nagy,et al.  Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. , 2008, Biophysical journal.

[47]  K. Wester,et al.  HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review , 2004, British Journal of Cancer.

[48]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[49]  G. Carpenter,et al.  Selective Cleavage of the Heregulin Receptor ErbB-4 by Protein Kinase C Activation* , 1996, The Journal of Biological Chemistry.

[50]  Jing Liu,et al.  Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185c-erbB-2 , 2003, Cell Research.

[51]  J. Janin,et al.  Dissecting protein–protein recognition sites , 2002, Proteins.

[52]  R. Ward,et al.  Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines , 2001, Cancer Immunology, Immunotherapy.

[53]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[54]  C. Chothia,et al.  The structure of protein-protein recognition sites. , 1990, The Journal of biological chemistry.

[55]  David Baker,et al.  Protein-protein docking with backbone flexibility. , 2007, Journal of molecular biology.

[56]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2007, Current protocols in protein science.

[57]  N. Pokala,et al.  Energy functions for protein design: adjustment with protein-protein complex affinities, models for the unfolded state, and negative design of solubility and specificity. , 2005, Journal of molecular biology.

[58]  Dennis R Livesay,et al.  Conserved sequence and structure association motifs in antibody-protein and antibody-hapten complexes. , 2004, Protein engineering, design & selection : PEDS.

[59]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.